Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
ProQuest Associates IV LLC (CIK 1431819) reported $53.0M across 4 reported positions in its SEC 13F filing for 2018-09-30. Largest positions: URGN ($37.3M, 70.39%), MRSN ($9.6M, 18.05%), IMDZ ($4.3M, 8.06%), AGRX ($1.9M, 3.50%), EGRX ($0, 0.00%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | URGN | UROGEN PHARMA LTD. | $37.3M | 70.39% | 789,297 | Hold |
| 2 | MRSN | MERSANA THERAPEUTICS, INC. | $9.6M | 18.05% | 955,709 | Hold |
| 3 | IMDZ | IMMUNE DESIGN CORP. | $4.3M | 8.06% | 1.2M | Hold |
| 4 | AGRX | AGILE THERAPEUTICS, INC. | $1.9M | 3.50% | 5.1M | Hold |
| 5 | EGRX | EAGLE PHARMACEUTICALS, INC. | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2018-09-30